| MediciNova Completes Enrollment in Phase 2 MN-221 Trial Treating Patients ... MarketWatch (press release) MN-221 is a novel, highly selective beta(2)-adrenergic receptor agonist in development for the treatment of acute exacerbations of asthma and COPD. An exacerbation is defined as an acute, long-lasting and severe asthma/COPD episode that is not ... See all stories on this topic » |
Wednesday, March 21, 2012
Acute asthma treatment
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment